Literature DB >> 18334619

The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor.

Susanne Schlisio1, Rajappa S Kenchappa, Liesbeth C W Vredeveld, Rani E George, Rodney Stewart, Heidi Greulich, Kristina Shahriari, Nguyen V Nguyen, Pascal Pigny, Patricia L Dahia, Scott L Pomeroy, John M Maris, A Thomas Look, Matthew Meyerson, Daniel S Peeper, Bruce D Carter, William G Kaelin.   

Abstract

VHL, NF-1, c-Ret, and Succinate Dehydrogenase Subunits B and D act on a developmental apoptotic pathway that is activated when nerve growth factor (NGF) becomes limiting for neuronal progenitor cells and requires the EglN3 prolyl hydroxylase as a downstream effector. Germline mutations of these genes cause familial pheochromocytoma and other neural crest-derived tumors. Using an unbiased shRNA screen we found that the kinesin KIF1Bbeta acts downstream from EglN3 and is both necessary and sufficient for neuronal apoptosis when NGF becomes limiting. KIF1Bbeta maps to chromosome 1p36.2, which is frequently deleted in neural crest-derived tumors including neuroblastomas. We identified inherited loss-of-function KIF1Bbeta missense mutations in neuroblastomas and pheochromocytomas and an acquired loss-of-function mutation in a medulloblastoma, arguing that KIF1Bbeta is a pathogenic target of these deletions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334619      PMCID: PMC2279200          DOI: 10.1101/gad.1648608

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  48 in total

1.  Induction of SM-20 in PC12 cells leads to increased cytochrome c levels, accumulation of cytochrome c in the cytosol, and caspase-dependent cell death.

Authors:  Jennifer A Straub; Elizabeth A Lipscomb; Eileen S Yoshida; Robert S Freeman
Journal:  J Neurochem       Date:  2003-04       Impact factor: 5.372

2.  Chromosomal aberrations in human neuroblastomas.

Authors:  G M Brodeur; G Sekhon; M N Goldstein
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

3.  Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2.

Authors:  Cecilia Krona; Katarina Ejeskär; Frida Abel; Per Kogner; Jill Bjelke; Elin Björk; Rose-Marie Sjöberg; Tommy Martinsson
Journal:  Oncogene       Date:  2003-04-17       Impact factor: 9.867

4.  Mutation and cancer: neuroblastoma and pheochromocytoma.

Authors:  A G Knudson; L C Strong
Journal:  Am J Hum Genet       Date:  1972-09       Impact factor: 11.025

5.  Stable suppression of tumorigenicity by virus-mediated RNA interference.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

6.  Fine analysis of the short arm of chromosome 1 in sporadic and familial pheochromocytoma.

Authors:  G Opocher; F Schiavi; A Vettori; F Pampinella; L Vitiello; A Calderan; B Vianello; A Murgia; M Martella; A Taccaliti; F Mantero; M L Mostacciuolo
Journal:  Clin Endocrinol (Oxf)       Date:  2003-12       Impact factor: 3.478

7.  HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia.

Authors:  Edurne Berra; Emmanuel Benizri; Amandine Ginouvès; Véronique Volmat; Danièle Roux; Jacques Pouysségur
Journal:  EMBO J       Date:  2003-08-15       Impact factor: 11.598

8.  Developmental genetics of neuroblastoma.

Authors:  A G Knudson; A T Meadows
Journal:  J Natl Cancer Inst       Date:  1976-09       Impact factor: 13.506

9.  A large-scale RNAi screen in human cells identifies new components of the p53 pathway.

Authors:  Katrien Berns; E Marielle Hijmans; Jasper Mullenders; Thijn R Brummelkamp; Arno Velds; Mike Heimerikx; Ron M Kerkhoven; Mandy Madiredjo; Wouter Nijkamp; Britta Weigelt; Reuven Agami; Wei Ge; Guy Cavet; Peter S Linsley; Roderick L Beijersbergen; René Bernards
Journal:  Nature       Date:  2004-03-25       Impact factor: 49.962

10.  c-jun is essential for sympathetic neuronal death induced by NGF withdrawal but not by p75 activation.

Authors:  M Palmada; S Kanwal; N J Rutkoski; C Gustafson-Brown; R S Johnson; R Wisdom; B D Carter; C Gufstafson-Brown
Journal:  J Cell Biol       Date:  2002-08-05       Impact factor: 10.539

View more
  131 in total

Review 1.  Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.

Authors:  Thamara E Osinga; Thera P Links; Robin P F Dullaart; Karel Pacak; Anouk N A van der Horst-Schrivers; Michiel N Kerstens; Ido P Kema
Journal:  FASEB J       Date:  2017-03-06       Impact factor: 5.191

2.  Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells.

Authors:  Heidi Högel; Krista Rantanen; Terhi Jokilehto; Reidar Grenman; Panu M Jaakkola
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

Review 3.  Unconventional functions of microtubule motors.

Authors:  Virgil Muresan; Zoia Muresan
Journal:  Arch Biochem Biophys       Date:  2012-01-28       Impact factor: 4.013

Review 4.  An update on the genetics of pheochromocytoma.

Authors:  D Karasek; U Shah; Z Frysak; C Stratakis; K Pacak
Journal:  J Hum Hypertens       Date:  2012-05-31       Impact factor: 3.012

5.  Role of SDHAF2 and SDHD in von Hippel-Lindau associated pheochromocytomas.

Authors:  Johan Kugelberg; Jenny Welander; Francesca Schiavi; Ambrogio Fassina; Martin Bäckdahl; Catharina Larsson; Giuseppe Opocher; Peter Söderkvist; Patricia L Dahia; Hartmut P H Neumann; Oliver Gimm
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

6.  Nervous system: Embryonal tumors: Neuroblastoma.

Authors:  Caileigh Pudela; Skye Balyasny; Mark A Applebaum
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2020-07

Review 7.  Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.

Authors:  J Matro; A Giubellino; K Pacak
Journal:  Horm Metab Res       Date:  2013-01-15       Impact factor: 2.936

8.  Pheochromocytoma and paraganglioma syndromes: genetics and management update.

Authors:  M Lefebvre; W D Foulkes
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

9.  EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance.

Authors:  Shuijie Li; Javier Rodriguez; Wenyu Li; Petra Bullova; Stuart M Fell; Olga Surova; Isabelle Westerlund; Danijal Topcic; Maria Bergsland; Adam Stenman; Jonas Muhr; Monica Nistér; Johan Holmberg; C Christofer Juhlin; Catharina Larsson; Alex von Kriegsheim; William G Kaelin; Susanne Schlisio
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-02       Impact factor: 11.205

10.  Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas.

Authors:  Esmeralda Castelblanco; Maria Santacana; Joan Valls; Aguirre de Cubas; Alberto Cascón; Mercedes Robledo; Xavier Matias-Guiu
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.